Trastuzumab Injection Uses, Dosage, Side Effects and Interactions
Herceptin
Herceptin is the original trastuzumab, made by Genentech. Its biosimilars are Ogivri, Herzuma, Ontruzant and Trazimera, and 2 more. It comes as an injection.
Herzuma
Herzuma (trastuzumab-pkrb) is Celltrion’s biosimilar to Herceptin, approved by the FDA in December 2018. The FDA has not rated it interchangeable with Herceptin. It comes as an injection.
Kanjinti
Kanjinti (trastuzumab-anns) is Amgen’s biosimilar to Herceptin, approved by the FDA in June 2019. The FDA has not rated it interchangeable with Herceptin.
Ogivri
Ogivri (trastuzumab-dkst) is Biocon Biologics’s biosimilar to Herceptin, approved by the FDA in December 2017. The FDA has not rated it interchangeable with Herceptin. It comes as an injection.
Trazimera
Trazimera (trastuzumab-qyyp) is Pfizer Ireland Pharmaceuticals’s biosimilar to Herceptin, approved by the FDA in March 2019. The FDA has not rated it interchangeable with Herceptin.
Ontruzant
Ontruzant (trastuzumab-dttb) is Samsung Bioepis’s biosimilar to Herceptin, approved by the FDA in January 2019. The FDA has not rated it interchangeable with Herceptin. It comes as an injection.
Hercessi
Hercessi (trastuzumab-strf) is Accord BioPharma’s biosimilar to Herceptin, approved by the FDA in April 2024. The FDA has not rated it interchangeable with Herceptin.
Herceptin is the original trastuzumab. The FDA has approved 6 biosimilars of it, such as Ogivri and Herzuma, and they share this page. What is a biosimilar? ↓
Trastuzumab Injection is an intravenous (IV) medicine that targets HER2, used to treat HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction cancer.
Quick links
Ask Anything About Trastuzumab InjectionType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Trastuzumab Injection in Short
- Drug class HER2/neu Receptor Antagonist How the FDA classifies it
What it treatsTrastuzumab products are used in adults whose tumors overexpress HER2 (have too much of a protein called HER2). Your tumor must be tested with an FDA-approved test before treatment.
- How you get it Prescription only
- Comes asInjection (into a vein)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
The Pharmacist’s Take
Trastuzumab is a targeted antibody for breast cancer and advanced stomach or gastroesophageal junction (where the esophagus joins the stomach) cancer whose tumors make too much HER2, a growth protein; it slows those cells and helps the immune system attack them, and it has anchored HER2-positive treatment since about 1998, with several FDA-licensed biosimilar versions. Many people tolerate it better than the chemotherapy it usually joins; fever and chills with the first infusion, tiredness and diarrhea are most common. Its boxed warning covers heart weakening, serious infusion and lung reactions, and harm to an unborn baby, so report new breathlessness, ankle swelling, a racing heartbeat or sudden weight gain.
Key Takeaways From the HelloPharmacist Team
- Expect a clinic IV infusion weekly or every three weeks, the first one longer, for about a year in early breast cancer.
- Plan on a heart scan before starting and about every 3 months during treatment, since heart weakening can happen without symptoms.
- Report trouble breathing, dizziness or face or throat swelling right away, whether during the infusion or within the next 24 hours.
- If you could become pregnant, use effective birth control throughout treatment and for 7 months after the last dose.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Trastuzumab Injection.
Trastuzumab products can cause serious heart problems, serious infusion and lung reactions, and harm to an unborn baby.
- Heart: It can weaken the heart, causing heart failure or a drop in heart pumping function (LVEF), even without symptoms. Risk is highest with anthracycline chemotherapy. Heart function is checked before and during treatment, and treatment is stopped or paused if it drops significantly.
- Infusion reactions and lungs: Serious and fatal reactions can occur, usually during or within 24 hours of an infusion. Warning signs include trouble breathing, low blood pressure, and swelling of the face or throat. Treatment is stopped for anaphylaxis, angioedema, interstitial pneumonitis (lung inflammation), or acute respiratory distress syndrome.
- Pregnancy: It can cause low amniotic fluid (oligohydramnios), which can lead to underdeveloped lungs, skeletal problems and newborn death. Effective birth control is needed.
Patient Information Guide for Trastuzumab Injection
What It’s Used For
Trastuzumab Injection treats cancers that overexpress HER2, confirmed by an FDA-approved test.
- Herzuma: adjuvant (early-stage) HER2-overexpressing breast cancer, node positive or node negative, as part of specific chemotherapy regimens or as a single agent after anthracycline-based therapy.
- Herzuma: metastatic HER2-overexpressing breast cancer, with paclitaxel as first treatment or alone after prior chemotherapy for metastatic disease.
- Herzuma: HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, with cisplatin and capecitabine or 5-fluorouracil, in people not previously treated for metastatic disease.
How It Works
HER2 is a receptor on the surface of cells that can drive tumor growth when there is too much of it. Trastuzumab products slow the growth of tumor cells that overexpress HER2.
They also trigger antibody-dependent cellular cytotoxicity (ADCC), in which immune cells attack the tumor cell. This effect is stronger against HER2-overexpressing cancer cells than against cells without extra HER2.
Drug Class
Drug Class
- HER2/neu Receptor Antagonist
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- HER2/neu Receptor Antagonist
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- HER2/Neu/cerbB2 Antagonists
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Trastuzumab Injection in the FDA’s index.
From our Patient Information GuideHER2 is a receptor on the surface of cells that can drive tumor growth when there is too much of it. Trastuzumab products slow the growth of tumor cells that overexpress HER2. Read How Trastuzumab Injection Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Trastuzumab Injection in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Herceptin and Its Biosimilars
The FDA has approved 6 biosimilars to Herceptin, the original trastuzumab, made by Genentech. It rates none of them interchangeable.
The original
Herceptin
trastuzumab
Made by Genentech · FDA‑approved 1998
Its 6 biosimilars
- Ogivri trastuzumab-dkst Made by Biocon Biologics · FDA‑approved December 2017 Biosimilar, not rated interchangeable
- Herzuma trastuzumab-pkrb Made by Celltrion · FDA‑approved December 2018 Biosimilar, not rated interchangeable
- Ontruzant trastuzumab-dttb Made by Samsung Bioepis · FDA‑approved January 2019 Biosimilar, not rated interchangeable
- Trazimera trastuzumab-qyyp Made by Pfizer Ireland Pharmaceuticals · FDA‑approved March 2019 Biosimilar, not rated interchangeable
- Kanjinti trastuzumab-anns Made by Amgen · FDA‑approved June 2019 Biosimilar, not rated interchangeable
- Hercessi trastuzumab-strf Made by Accord BioPharma · FDA‑approved April 2024 Biosimilar, not rated interchangeable
What Is a Biosimilar?
- A biologic is made in living cells, not mixed from chemicals, so no copy of one is exactly identical. That is why a copy is called a biosimilar, not a generic.
- The FDA approves a biosimilar only when it is highly similar to the original and has no clinically meaningful differences in safety or in how well it works.
- It may be approved for fewer uses than the original, and may not come in every strength or device. Its own label lists what it is approved for.
What Does Interchangeable Mean?
- An interchangeable biosimilar can be given in place of the original at the pharmacy without your prescriber writing a new prescription, where state law allows, the way a generic can.
- A biosimilar without that rating works the same way, but needs a prescription written for it.
Why Four Letters After the Name?
- The FDA gives each biologic it licenses now four letters of its own, such as the letters dkst in trastuzumab-dkst. They mean nothing on their own.
- They tell one company’s product from another’s in your records and in safety reports.
Which one will I get? That depends on your prescription, your insurance plan and your pharmacy. Your pharmacist can tell you which one you have and whether a switch is possible.
From the FDA’s Purple Book, its list of licensed biologics, checked November 2026. The definitions follow the FDA’s biosimilar pages.
Dosage
Trastuzumab Injection is given as an IV infusion by a healthcare professional. Food does not apply.
- Breast cancer: given weekly or every three weeks. Adjuvant treatment totals about one year, and extending beyond one year is not recommended.
- Metastatic breast or gastric cancer: continues until the disease progresses.
- The first infusion is longer than later ones. Infusions may be slowed or stopped if a reaction occurs.
- Missed dose: if you are one week late or less, the usual dose is given as soon as possible. If more than a week late, a larger re-loading dose is given. Call your care team to reschedule.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Adjuvant breast cancer, during and following paclitaxel, docetaxel, or docetaxel and carboplatin: initial dose
Adults given with paclitaxel, docetaxel, or docetaxel and carboplatin · Initial dose Starting dose 4 mg/kg once
- 4 mg/kg as an intravenous infusion over 90 minutes
Adults given with paclitaxel, docetaxel, or docetaxel and carboplatin · Every three weeks after the weekly doses Usual dose 6 mg/kg every three weeks
- 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks, starting one week following the last weekly dose, for a total of 52 weeks of therapy
Good to know
Extending adjuvant treatment beyond one year is not recommended
Early-stage HER2-positive breast cancer (after surgery)
For adults given with paclitaxel, docetaxel, or docetaxel and carboplatin · Weekly doses during chemotherapy
Usual dose 2 mg/kg once a week
- 2 mg/kg as an intravenous infusion over 30 minutes weekly during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel and carboplatin)
Adjuvant breast cancer, as a single agent within three weeks following multi-modality, anthracycline-based chemotherapy: initial dose
Adults given alone after anthracycline-based chemotherapy · Initial dose Starting dose 8 mg/kg once
- 8 mg/kg as an intravenous infusion over 90 minutes
Adults given alone after anthracycline-based chemotherapy · Subsequent doses Usual dose 6 mg/kg every three weeks
- 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks
Good to know
Total of 52 weeks of therapy; extending beyond one year is not recommended
Metastatic breast cancer, alone or in combination with paclitaxel: initial dose
For adults · Initial dose
Starting dose 4 mg/kg once
- 4 mg/kg as a 90-minute intravenous infusion
HER2-positive breast cancer that has spread
For adults · Subsequent weekly doses
Usual dose 2 mg/kg once a week
- 2 mg/kg as 30-minute intravenous infusions once weekly until disease progression
Metastatic gastric cancer: initial dose
For adults · Initial dose
Starting dose 8 mg/kg once
- 8 mg/kg as a 90-minute intravenous infusion
Metastatic gastric cancer: subsequent doses
For adults · Subsequent doses
Usual dose 6 mg/kg every three weeks
- 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease progression
Side Effects
Common side effects vary by cancer type and by the chemotherapy given with it.
Common side effects
- Fever and chills
- Nausea and vomiting
- Diarrhea
- Headache
- Fatigue or weakness
- Cough and shortness of breath
- Rash
- Infections and low white blood cell counts (neutropenia)
- Muscle pain (myalgia)
When to get medical help
- Call your doctor right away for new shortness of breath, swelling in the legs or ankles, rapid heartbeat or palpitations, or sudden weight gain, which can be signs of heart problems.
- Tell your care team immediately during or after an infusion if you have trouble breathing, dizziness, lightheadedness, facial or throat swelling, or severe rash. Serious and fatal infusion reactions can occur, usually within 24 hours.
- Report new or worsening cough, trouble breathing, or breathing problems, which may signal lung toxicity.
- Call right away if you have fever or signs of infection, since trastuzumab can worsen chemotherapy-related low white blood cell counts.
- Tell your doctor right away if you are or may be pregnant.
Warnings and Precautions
- Heart problems: trastuzumab can cause cardiomyopathy, heart failure, arrhythmias and a drop in LVEF, especially with anthracyclines. Heart function is tested before and during treatment.
- Infusion reactions: can be serious or fatal, usually during or within 24 hours of an infusion.
- Lung toxicity: includes pneumonitis, fluid around the lungs and ARDS. People with lung disease or extensive lung tumors may have more severe reactions.
- Pregnancy harm: can cause oligohydramnios and fetal harm.
- Neutropenia: low white blood cell counts may be worse when it is combined with chemotherapy.
Interactions
No formal drug interaction studies were done in humans, but anthracyclines are an important concern.
- Anthracyclines (such as doxorubicin): raise the risk of heart problems, including after trastuzumab is stopped because it clears slowly.
- Ado-trastuzumab emtansine and fam-trastuzumab deruxtecan: different drugs, never interchangeable with trastuzumab products.
- Paclitaxel, docetaxel, carboplatin, cisplatin, capecitabine: levels were not changed by trastuzumab in studies.
Interactions Listed in the FDA-Approved Label
From the Trastuzumab Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
AnthracyclinesWhat happensPatients who receive an anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab's long washout period.What to doIf possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products; if anthracyclines are used, monitor cardiac function carefully.
Read the label’s full interactions text
7 DRUG INTERACTIONS Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab’s long washout period based on population PK analysis. If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, the patient’s cardiac function should be monitored carefully.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Tell your doctor about heart or lung disease.
- Pregnancy status is checked before starting. Use effective birth control during treatment and for 7 months after the last dose.
- If breastfeeding, discuss benefits and risks with your doctor.
- Adults 65 and over had a higher risk of heart dysfunction.
- Safety and effectiveness in children have not been established.
- No contraindications are listed.
Overdose
There is no experience with overdose in human clinical trials. Single doses higher than 8 mg/kg have not been tested.
How Your Body Processes It
Trastuzumab is cleared by two pathways, and clearance increases as drug levels fall. Steady-state levels were reached in about 9 to 12 weeks in the studies. After stopping, levels fall to about 3% of steady-state levels by 7 months in most patients, which is why precautions last that long.
Age, race and mild to moderate kidney impairment did not cause meaningful differences. Effects of severe kidney impairment or liver impairment are unknown.
Storage
Store Herceptin vials in the refrigerator at 2°C to 8°C (36°F to 46°F) until time of reconstitution.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Trastuzumab Injection: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Trastuzumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is trastuzumab injection used for?
How is trastuzumab injection given?
What happens if I miss a dose of trastuzumab injection?
What side effects should I expect, and which should I call about?
Is it safe during pregnancy?
How long does Trastuzumab stay in my body?
Is trastuzumab injection available over the counter?
When was trastuzumab injection first available?
Who makes trastuzumab injection?
What is the brand name of trastuzumab injection?
What is the generic name of Herceptin?
What drug class is trastuzumab injection?
What strengths does trastuzumab injection come in?
Where can I read the trastuzumab injection prescribing information (package insert)?
Is there a biosimilar for Herceptin?
Is trastuzumab injection gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Trastuzumab Injection
Skip the scrolling. Ask in your own words and get an answer from Trastuzumab Injection’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Trastuzumab Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Trastuzumab Injection on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Trastuzumab Injection Forms and Strengths (How It Comes)
Trastuzumab Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Trastuzumab Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Herzuma is used in adults for HER2-overexpressing breast cancer, including adjuvant and metastatic settings.
- Herzuma is also used with cisplatin and capecitabine or 5-fluorouracil for HER2-overexpressing metastatic gastric or gastroesophageal junction cancer in people not previously treated for metastatic disease.
- Herzuma is for IV infusion only and must not be given as an IV push or bolus.
- Herzuma has different dosing and administration instructions than subcutaneous trastuzumab products.
- Herzuma must not be substituted for or with ado-trastuzumab emtansine or fam-trastuzumab deruxtecan.
- Herzuma is not mixed with other drugs and is diluted in 0.9% sodium chloride, not dextrose.
Trastuzumab Injection on the U.S. Market: Products, Makers and Brands
How Trastuzumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
5 companies list 5 Trastuzumab Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1998. Brand names in the directory today include Herceptin, Herzuma, Ogivri and 1 more; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished injection (2) · Unfinished injection, powder, lyophilized, for solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Trastuzumab Injection Is Used (Medicaid Data)
How many Trastuzumab Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Trastuzumab Injection prescribed? Of the 1,682 medications we measure, Trastuzumab Injection ranks #659 by Medicaid prescriptions — more than 61% of them.
Utilization by Trastuzumab Injection product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
fam-trastuzumab deruxtecan-nxki 100 MG Injection Most dispensed
1 of 1 listed NDCs had Medicaid claims. RxNorm 2267576
trastuzumab-dkst 21 MG/ML Injectable Solution
2 of 5 listed NDCs had Medicaid claims. RxNorm 2179760
trastuzumab 150 MG Injection
1 of 2 listed NDCs had Medicaid claims. RxNorm 1922509
ado-trastuzumab emtansine 100 MG Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 1658084
trastuzumab-qyyp 21 MG/ML Injectable Solution
1 of 2 listed NDCs had Medicaid claims. RxNorm 2280732
trastuzumab-anns 21 MG/ML Injectable Solution
2 of 3 listed NDCs had Medicaid claims. RxNorm 2174804
ado-trastuzumab emtansine 160 MG Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 1658089
trastuzumab-anns 150 MG Injection
1 of 2 listed NDCs had Medicaid claims. RxNorm 2257297
trastuzumab-dkst 150 MG Injection
2 of 2 listed NDCs had Medicaid claims. RxNorm 2179753
trastuzumab-qyyp 150 MG Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 2472791
trastuzumab-dttb 21 MG/ML Injectable Solution
1 of 3 listed NDCs had Medicaid claims. RxNorm 2289234
trastuzumab-dttb 150 MG Injection
1 of 4 listed NDCs had Medicaid claims. RxNorm 2289227
trastuzumab-pkrb 21 MG/ML Injectable Solution
1 of 2 listed NDCs had Medicaid claims. RxNorm 2107053
trastuzumab-pkrb 150 MG Injection
1 of 1 listed NDCs had Medicaid claims. RxNorm 2169359
Other Trastuzumab Injection products: packs and listings not matched to one strength and form
2 of 17 listed NDCs had Medicaid claims.
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 19 of the 47 listed Trastuzumab Injection NDCs had Medicaid claims.
Compare Trastuzumab Injection Products
A representative set of FDA-listed product records for Trastuzumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 150 mg/7.4 mL | Intravenous | Biocon Biologics Inc. | BLA | View NDC → |
| 150 mg/7.15 mL | Intravenous | Cephalon, Inc. | BLA | View NDC → |
| 150 mg/7.4 mL | Intravenous | Genentech, Inc. | BLA | View NDC → |
| 150 mg/7.4 mL | Intravenous | Mylan Institutional LLC | BLA | View NDC → |
| 150 mg | Intravenous | Organon LLC | BLA | View NDC → |
Showing 5 of 5 products — FDA National Drug Code Directory. See every product, package size and price: browse all 5 Trastuzumab Injection NDCs →
Trastuzumab Injection Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Trastuzumab Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Trastuzumab Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Trastuzumab Injection FDA Approval History
How Trastuzumab Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Trastuzumab Injection Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Trastuzumab recalls since July 2021.
✅No Trastuzumab recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Trastuzumab Injection in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 2
- Strengths
- 17
- Forms in current FDA listings
- 2 of 2
RxCUI 224905 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1922508Its 10 strengths (SCD)-
150 mg
RxCUI 1922509 -
100 mg
ado-trastuzumab emtansine
RxCUI 1658084 -
160 mg
ado-trastuzumab emtansine
RxCUI 1658089 -
150 mg
anns
RxCUI 2257297 -
150 mg
dkst
RxCUI 2179753 -
150 mg
dttb
RxCUI 2289227 -
100 mg
fam-trastuzumab deruxtecan-nxki
RxCUI 2267576 -
150 mg
pkrb
RxCUI 2169359 -
150 mg
qyyp
RxCUI 2472791 -
150 mg
strf
RxCUI 2700718
-
150 mg
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Trastuzumab Injection Supply and Shortage Status
Whether Trastuzumab Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Trastuzumab Injection Brand Names
Trastuzumab Injection has 7 brand names on record: Herceptin, Herzuma, Kanjinti, Ogivri and others. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Trastuzumab Injection: Manufacturers and Labelers
5 companies list Trastuzumab Injection products with the FDA. By number of product records, the largest are Biocon Biologics Inc., Cephalon, Inc., Genentech, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Trastuzumab Injection Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Genentech, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →